Literature DB >> 18433021

MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations.

Yannick Ladeiro1, Gabrielle Couchy, Charles Balabaud, Paulette Bioulac-Sage, Laura Pelletier, Sandra Rebouissou, Jessica Zucman-Rossi.   

Abstract

UNLABELLED: Molecular classifications defining new tumor subtypes have been recently refined with genetic and transcriptomic analyses of benign and malignant hepatocellular tumors. Here, we performed microRNA (miRNA) profiling in two series of fully annotated liver tumors to uncover associations between oncogene/tumor suppressor mutations and clinical and pathological features. Expression levels of 250 miRNAs in 46 benign and malignant hepatocellular tumors were compared to those of 4 normal liver samples with quantitative reverse-transcriptase polymerase chain reaction. miRNAs associated with genetic and clinical characteristics were validated in a second series of 43 liver tumor samples and 16 nontumor samples. miRNA profiling unsupervised analysis classified samples in unique clusters characterized by histological features (tumor/nontumor, P < 0.001; benign/malignant tumors, P < 0.01; inflammatory adenoma and focal nodular hyperplasia, P < 0.01), clinical characteristics [hepatitis B virus (HBV) infection, P < 0.001; alcohol consumption, P < 0.05], and oncogene/tumor suppressor gene mutations [beta-catenin, P < 0.01; hepatocyte nuclear factor 1alpha (HNF1alpha), P < 0.01]. Our study identified and validated miR-224 overexpression in all tumors and miR-200c, miR-200, miR-21, miR-224, miR-10b, and miR-222 specific deregulation in benign or malignant tumors. Moreover, miR-96 was overexpressed in HBV tumors, and miR-126* was down-regulated in alcohol-related hepatocellular carcinoma. Down-regulations of miR-107 and miR-375 were specifically associated with HNF1alpha and beta-catenin gene mutations, respectively. miR-375 expression was highly correlated to that of beta-catenin-targeted genes as miR-107 expression was correlated to that of HNF1alpha in a small interfering RNA cell line model. Thus, this strongly suggests that beta-catenin and HNF1alpha could regulate miR-375 and miR-107 expression levels, respectively.
CONCLUSION: Hepatocellular tumors may have a distinct miRNA expression fingerprint according to malignancy, risk factors, and oncogene/tumor suppressor gene alterations. Dissecting these relationships provides a new hypothesis to understand the functional impact of miRNA deregulation in liver tumorigenesis and the promising use of miRNAs as diagnostic markers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18433021     DOI: 10.1002/hep.22256

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  270 in total

Review 1.  MicroRNAs in liver disease.

Authors:  Xin Wei Wang; Niels H H Heegaard; Henrik Orum
Journal:  Gastroenterology       Date:  2012-04-11       Impact factor: 22.682

2.  Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma.

Authors:  Ya-Hui Huang; Kwang-Huei Lin; Hua-Chien Chen; Ming-Ling Chang; Chao-Wei Hsu; Ming-Wei Lai; Tse-Ching Chen; Wei-Chen Lee; Yi-Hsin Tseng; Chau-Ting Yeh
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

3.  MicroRNA-200b regulates cyclin D1 expression and promotes S-phase entry by targeting RND3 in HeLa cells.

Authors:  Wei Xia; Jie Li; Liucun Chen; Baochun Huang; Shaohua Li; Guang Yang; Hongmei Ding; Fang Wang; Nongle Liu; Qiang Zhao; Tao Fang; Tao Song; Tianyou Wang; Ningsheng Shao
Journal:  Mol Cell Biochem       Date:  2010-08-04       Impact factor: 3.396

Review 4.  The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer?

Authors:  Simone Brabletz; Thomas Brabletz
Journal:  EMBO Rep       Date:  2010-08-13       Impact factor: 8.807

5.  Function and clinical potential of microRNAs in hepatocellular carcinoma.

Authors:  Lijuan Wang; Yongfang Yue; Xian Wang; Hongchuan Jin
Journal:  Oncol Lett       Date:  2015-09-29       Impact factor: 2.967

6.  Combination of exosomes and circulating microRNAs may serve as a promising tumor marker complementary to alpha-fetoprotein for early-stage hepatocellular carcinoma diagnosis in rats.

Authors:  Wei-hui Liu; Li-na Ren; Xing Wang; Tao Wang; Ning Zhang; Yuan Gao; Hao Luo; Nalu Navarro-Alvarez; Li-jun Tang
Journal:  J Cancer Res Clin Oncol       Date:  2015-02-28       Impact factor: 4.553

7.  Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma.

Authors:  Giacomo Diaz; Marta Melis; Ashley Tice; David E Kleiner; Lopa Mishra; Fausto Zamboni; Patrizia Farci
Journal:  Int J Cancer       Date:  2013-03-16       Impact factor: 7.396

Review 8.  Role of innate immunity in the development of hepatocellular carcinoma.

Authors:  Rajagopal N Aravalli
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

9.  miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells.

Authors:  Jing Zhang; Jingjing Jiao; Silvia Cermelli; Kyle Muir; Kwang Hwa Jung; Ruhai Zou; Asif Rashid; Mihai Gagea; Sonya Zabludoff; Raghu Kalluri; Laura Beretta
Journal:  Cancer Res       Date:  2015-03-13       Impact factor: 12.701

10.  MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3.

Authors:  Florin M Selaru; Alexandru V Olaru; Takatsugu Kan; Stefan David; Yulan Cheng; Yuriko Mori; Jian Yang; Bogdan Paun; Zhe Jin; Rachana Agarwal; James P Hamilton; John Abraham; Christos Georgiades; Hector Alvarez; Perumal Vivekanandan; Wayne Yu; Anirban Maitra; Michael Torbenson; Paul J Thuluvath; Gregory J Gores; Nicholas F LaRusso; Ralph Hruban; Stephen J Meltzer
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.